BNET Industries
Last Fiscal Year Sales:$1.4M
- Public
- US
Dow Jones Description
Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. The Company's strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has two products currently being sold commercially and a pipeline of five drug products under development in the therapeutic areas that include pain management, allergy and infection. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
Director, President and Chief Executive Officer
Bernard BerkNumber of Employees 12
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Elite Pharmaceuticals, Inc. Announces Second Closing of Strategic Alliance Agreement...
-
Elite Pharmaceuticals names new CEO and chief scientific officer
-
Elite Pharmaceuticals ELTP Appoints Jerry I. Treppel, Current Chairman, as CEO
-
Week of Sept. 21, 2009: AstraZeneca and Nektar Sign License Agreement; Eli Lilly Names President...
-
Elite Pharma Appoints Carter Ward As CFO - Quick Facts
-
Elite Announces New Chief Financial Officer
-
Elite Announces Initial Closing Under Strategic Alliance Agreement
News & Analysis
Filter by
elite pharmaceuticals inc. - All News and Analysis
Elite Grants Purdue Exclusive Right to Evaluate Its Abuse Resistance Drug Formulation Technology
Business Editors/Health/Medical Writers BIOWIRE2K NORTHVALE, N.J.--BUSINESS WIRE--May 10, 2004 Elite Pharmaceuticals, Inc. (AMEX:ELI) today announced an agreement between its wholly owned subsidiary, Elite Laboratories, Inc., and Purdue Pharma L.P. through which Elite grants Purdue the exclusive right to evaluate certain Elite abuse resistance drug formulation technology and...
Elite Pharmaceuticals, Inc. CEO Atul Mehta talks to The Wall Street Transcript
NEW YORK--BUSINESS WIRE--Feb. 1, 1999--The Wall Street Transcript has published an in-depth interview with Dr. Atul M. Mehta of Elite pharmaceuticals, Inc. (OTC BB: ELIP), in which he talks at length about his company's future. He says, "We specialize in developing oral drug delivery systems mainly for prescription drug...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Bernard Berk | Director, President and Chief Executive Officer |
| Mark I Gittelman | Chief Financial Officer |
| Stuart C Apfel | Chief Scientific Officer and Chief Medical Officer |
| Veerappan Subramanian | Director, Chief Scientific Officer |
| Dr Charan Behl | Executive Vice President |
| Christopher W Dick | Vice President |
| Barry H Dash | Director |
| Melvin Van Woert | Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Edward Neugeboren | Board of Directors |
| Jerry I. Treppel | Board of Directors |
| Robert J. Levenson | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Director, President and Chief Executive Officer | Current |
| Elite Research, Inc. | CEO | Current |
| Elite Laboratories, Inc. | CEO | Current |
| Elite Pharmaceuticals, Inc. | Chairman, CEO, President | Current |
| Elite Pharmaceuticals, Inc. | Director | Former |
| New York University | B.S. | Former |
MARK I. GITTELMAN, Chief Financial Officer, Secretary and Treasurer of the Company, is the President of Gittelman & Co., P.C., an accounting firm in Clifton, New Jersey. Prior to forming Gittelman & Co., P.C. in 1984, he worked as a certified public accountant with the international accounting firm of KPMG Peat Marwick, LLP. Mr. Gittelman holds a B.S. in accounting from New York University and a Masters of Science in Taxation from Fairleigh Dickinson University. He is a Certified Public Accountant licensed in New Jersey and New York, and is a member of the American Institute of Certified Public Accountants ("AICPA"), and the New Jersey State and New York State Societies of CPAs. Other than Elite Labs, no company with which Mr. Gittelman was affiliated in the past was a parent, subsidiary or other affiliate of the Company.
| Organization | Position | Status |
|---|---|---|
| Gittelman & Company | President | Current |
| Elite Pharmaceuticals, Inc. | Chief Financial Officer | Current |
| New Jersey State Society | Current | |
| New Jersey & Company | Board of Directors | Current |
| New-Jersey-State.Com | Board of Directors | Current |
| American Institute of Certified Public Accountants | Board of Directors | Current |
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| American Institute of Certified Public Accountants | Member | Current |
| New-Jersey-State.Com | Member | Current |
| American Institute of Certified Public Accountants | Member | Current |
| Gittelman & Company | Founder | Former |
| KPMG International | Former | |
| Gittelman & Company | Certified Public Accountant | Current |
| New York University | B.S. In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Desmoid Tumor Research Foundation, Inc | President of Parallax Clinical Research | Current |
| Parallax Clinical Research, LLC | President | Current |
| Elite Pharmaceuticals, Inc. | Chief Scientific Officer and Chief Medical Officer | Current |
| Parallax Clinical Research, LLC | Founder | Current |
| Albert Einstein College | Associate Professor | Current |
| Desmoid Tumor Research Foundation, Inc | Board of Directors | Current |
| Purdue Pharma L.P. | Associate Director of Clinical Research | Former |
| Neuroscience, Inc | Board of Directors | Former |
| Albert Einstein College | Board of Directors | Former |
| Columbia University | Undergraduate Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Director, Chief Scientific Officer | Current |
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Rutgers University | Ph.D. In Pharmacy | Former |
| Birla Institute of Technology & Science | M.S. In Phamaceutics | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Executive Vice President | Current |
| University of Michigan | Assistant Research Scientist | Former |
| Aaps | Chairman | Former |
| Duquesne University | M.S. in Pharmaceutics | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Vice President | Current |
| Ascent Venture Partners | Managing Director | Current |
| Sensitech Inc. | Director | Current |
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Whaleback Systems | Director | Current |
| eCopy, Inc. | Director | Current |
| UST Inc. | President, Venture Capital | Former |
| Elan Drug Delivery, Inc. | Director of Business Development | Former |
| Entec | Manager | Former |
| Elite Pharmaceuticals, Inc. | Executive | Former |
| National Association of Small Business Investment Companies | Member | Former |
| FMC Corporation | Former | |
| Ascent Corp | Former | |
| Harvard Bioscience, Inc. | Director | Former |
| Security Source, Inc. | Director | Former |
| Performance Polymers Inc. | Director | Former |
| Phoenix Controls Corporation | Director | Former |
| Cedar Point Communications, Inc. | Director | Former |
| Entigo Corporation | Director | Former |
| Babson College | MBA | Former |
| New York University | M.B.A. | Former |
| Cornell University | M.S. In Chemical Engineering | Former |
| Cornell University | BS in Agricultural Economics | Former |
| Organization | Position | Status |
|---|---|---|
| American Pharmaceutical Association | Board of Directors | Current |
| Geopharma, Inc. | Director | Current |
| Runonideas.Com | Director | Current |
| Redchip Companies, Inc. | Director | Current |
| Elite Pharmaceuticals, Inc. | Director | Current |
| American Pharmaceutical Association | Member | Current |
| Advanced Technologies Corp. | Senior Vice President | Former |
| American Home Products Corporation | Vice President of Scientific Affairs | Former |
| Advanced Technologies Corp. | Vice President of Scientific Affairs | Former |
| J. B. Williams | Former | |
| University of Florida | Ph.D. | Former |
| Columbia University | MS In Pharmacy | Former |
| Columbia University | BS In Pharmaceutical Sciences | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Lehman Brothers Holdings Inc. | Chief Administrative Officer | Former |
| Lehman Brothers Holdings Inc. | director of Equity Research Operations | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Akorn, Inc. | Board of Directors | Current |
| Merrill Lynch & Co., Inc. | Healthcare Services Analyst | Former |
| Able Laboratories, Inc. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Emisphere Technologies, Inc. | Director, Conferences | Former |
| Emisphere Technologies, Inc. | Director | Former |
| The Office of The President | Board of Directors | Former |
Dr. Melvin Van Woert, a neurologist, has been, since 1974, a member of the staff of Mount Sinai Medical Center where he has been a Professor of the Department of Neurology and Pharmacology at Mount Sinai School of Medicine since 1978. Dr. Van Woert had been a consultant for Neuropharmacological Drug Products to the Food and Drug Administration from 1974 to 1980; Associate Editor for Journal of the Neurological Sciences; Member of the Editorial Board of Journal of Clinical Neurphamacology; and Medical Director of National Organization for Rare Disorders for which he received in 1993 the Humanitarian Award. His other awards include the U.S. Public Health Service Award for Exceptional Achievement in Orphan Products Development and the National Myoclonus Foundation Award. He has authored and co-authored more than 150 articles appearing in pharmacological, medical and other professional journals or publications.
| Organization | Position | Status |
|---|---|---|
| Mount Sinai School of Medicine | Professor of the Department | Current |
| Elite Pharmaceuticals, Inc. | Member | Current |
| Elite Pharmaceuticals, Inc. | Director | Current |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

